---
title: "Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%"
description: "C4 Therapeutics, Inc. (NASDAQ:CCCC) shares have plummeted 40% in the past month, marking an 82% decline over the year. Despite a low price-to-sales (P/S) ratio of 2.5x, indicating potential buying opp"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/236610913.md"
published_at: "2025-04-18T15:26:12.000Z"
---

# Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%

> C4 Therapeutics, Inc. (NASDAQ:CCCC) shares have plummeted 40% in the past month, marking an 82% decline over the year. Despite a low price-to-sales (P/S) ratio of 2.5x, indicating potential buying opportunities, the company's revenue growth has been disappointing, with forecasts predicting a 20% annual decline over the next three years. Analysts suggest that the low P/S reflects market skepticism about future revenue performance, making a strong share price recovery unlikely in the near term. Additionally, there are four warning signs to consider regarding the company's financial health.

Unfortunately for some shareholders, the **C4 Therapeutics, Inc.** (NASDAQ:CCCC) share price has dived 40% in the last thirty days, prolonging recent pain. For any long-term shareholders, the last month ends a year to forget by locking in a 82% share price decline.

After such a large drop in price, C4 Therapeutics may look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 2.5x, considering almost half of all companies in the Biotechs industry in the United States have P/S ratios greater than 8.8x and even P/S higher than 51x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

See our latest analysis for C4 Therapeutics

### How Has C4 Therapeutics Performed Recently?

C4 Therapeutics could be doing better as it's been growing revenue less than most other companies lately. The P/S ratio is probably low because investors think this lacklustre revenue performance isn't going to get any better. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.

If you'd like to see what analysts are forecasting going forward, you should check out our **free** report on C4 Therapeutics.

## Is There Any Revenue Growth Forecasted For C4 Therapeutics?

The only time you'd be truly comfortable seeing a P/S as depressed as C4 Therapeutics' is when the company's growth is on track to lag the industry decidedly.

If we review the last year of revenue growth, the company posted a terrific increase of 71%. However, this wasn't enough as the latest three year period has seen the company endure a nasty 22% drop in revenue in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.

Looking ahead now, revenue is anticipated to slump, contracting by 20% per annum during the coming three years according to the eight analysts following the company. That's not great when the rest of the industry is expected to grow by 173% each year.

With this in consideration, we find it intriguing that C4 Therapeutics' P/S is closely matching its industry peers. However, shrinking revenues are unlikely to lead to a stable P/S over the longer term. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.

## The Bottom Line On C4 Therapeutics' P/S

Having almost fallen off a cliff, C4 Therapeutics' share price has pulled its P/S way down as well. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

As we suspected, our examination of C4 Therapeutics' analyst forecasts revealed that its outlook for shrinking revenue is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.

And what about other risks? Every company has them, and we've spotted **4 warning signs for C4 Therapeutics** (of which 1 is concerning!) you should know about.

**If companies with solid past earnings growth is up your alley**, you may wish to see this **free** collection of other companies with strong earnings growth and low P/E ratios.

If you're looking to trade C4 Therapeutics, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

Sponsored Content

### Related Stocks

- [CCCC.US - C4 Therapeutics](https://longbridge.com/en/quote/CCCC.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| C4 Therapeutics 在古根海姆会议上规划 Cemsidomide II 期试验启动及 BCMA 联合用药计划 | C4 Therapeutics（纳斯达克代码：CCCC）高管在古根海姆会议上介绍了推进其多发性骨髓瘤项目和扩展其靶向蛋白降解平台的计划。他们计划在第四线及以上的治疗中启动 cemsidomide 这一关键药物的二期临床试验，并进行与 elr | [Link](https://longbridge.com/en/news/275695219.md) |
| 分析师下调了 C4 Therapeutics 在 2028 财年的每股收益预测 | C4 Therapeutics, Inc.（纳斯达克代码：CCCC）在其 2028 财年的每股收益（EPS）预测中被 Brookline Capital Management 下调，从 1.15 美元降至 0.13 美元。当前全年收益的共识 | [Link](https://longbridge.com/en/news/272938147.md) |
| C4 Therapeutics 的首席医疗官 Leonard Reyno 报告了出售普通股的消息 | C4 Therapeutics Inc. 首席医疗官 Leonard Reyno 在最近的监管文件中报告了普通股的出售。该文件可以通过提供的链接访问。此消息由 Public Technologies 生成，仅供信息参考，不应被视为财务、投资 | [Link](https://longbridge.com/en/news/272879413.md) |
| C4 Therapeutics 授予新员工股票期权以作为激励措施 | C4 Therapeutics Inc. 已向一名新员工授予 162,880 股普通股的非合格股票期权。行权价格设定为授予日期 2026 年 2 月 9 日的收盘价。期权将在四年内逐步归属，第一年周年时归属 25%，其余部分将在接下来的三十 | [Link](https://longbridge.com/en/news/275360756.md) |
| C4 Therapeutics 公布了其多年 Cemsidomide 临床战略 | C4 Therapeutics 宣布了一项多年的战略，以推进其主要的 IKZF1/3 降解剂 cemsidomide，目标是在多发性骨髓瘤中达到同类最佳的地位。关键计划包括在 2026 年第一季度启动二期临床试验，以及在 2026 年第二季 | [Link](https://longbridge.com/en/news/272552593.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
